Immune checkpoint inhibitors targeting the PD-1/PD-L1 interaction have been approved as basic clinical drugs in the treatment of melanoma, non-small cell lung cancer (NSCLC), renal carcinoma, and many other malignancies [23]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.